Search Results

We hope you find what you’re looking for. You can email us if you need additional help.

Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

VANCOUVER, BC – March 26, 2024 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is thrilled to announce it has

March 26, 2024

Optimi Health Corp.

21 Water St #600, Vancouver, BC V6B 1A1

Contact Information

E: investors@optimihealth.ca

T: +778-761-4551

Regulator Filings

Sedar Documents

Sedar Profile

Reporting – Modern Slavery Report 2024

Legal Counsel: Norton Rose Fulbright

Auditor: Smythe CPA

Transfer Agent: Endeavor Trust

Corporate Visibility & Investor Relations: Kydder Group

Trading Symbol: CSE: OPTI | OTC:OPTHF |

FRA: 8BN

CUSIP Number: 68405H100

ISIN Number: CA68405H1001

WKN: A2QQEL

Issued & Outstanding: (30/06/2022) 80,451,883

Incorporated: BC / May 27, 2020

Year End: September 30th

Privacy

Disclaimer

Product Disclaimer: Optimi Health products are still being investigated through a clinically validated development program for the purpose of applying for market authorization.

The safety and efficacy of our products has not been formally established.

Search Results

Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

Visit OptimiLife.com

Get news & updates directly to your inbox.

Interested In Optimi? Let's Talk.